Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study

  1. Usmani, S.Z.
  2. Garfall, A.L.
  3. van de Donk, N.W.C.J.
  4. Nahi, H.
  5. San-Miguel, J.F.
  6. Oriol, A.
  7. Rosinol, L.
  8. Chari, A.
  9. Bhutani, M.
  10. Karlin, L.
  11. Benboubker, L.
  12. Pei, L.
  13. Verona, R.
  14. Girgis, S.
  15. Stephenson, T.
  16. Elsayed, Y.
  17. Infante, J.
  18. Goldberg, J.D.
  19. Banerjee, A.
  20. Mateos, M.-V.
  21. Krishnan, A.
Journal:
The Lancet

ISSN: 1474-547X 0140-6736

Year of publication: 2021

Volume: 398

Issue: 10301

Pages: 665-674

Type: Article

DOI: 10.1016/S0140-6736(21)01338-6 GOOGLE SCHOLAR

Sustainable development goals